An open-label, randomized, two-period cross-over study of repeated subcutaneous injections of methotrexate 50mg/ml solution either by a pre-filled syringe (reference) or by a disposable pre-filled pen (test) to assess patient?s preference and self-injection experience and to compare the local tolerability in patients with active rheumatoid arthritis

Trial Profile

An open-label, randomized, two-period cross-over study of repeated subcutaneous injections of methotrexate 50mg/ml solution either by a pre-filled syringe (reference) or by a disposable pre-filled pen (test) to assess patient?s preference and self-injection experience and to compare the local tolerability in patients with active rheumatoid arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2013

At a glance

  • Drugs Methotrexate (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 May 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 18 Feb 2013 Planned end date changed from 31 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 18 Feb 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01793259).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top